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1061-95 Effect of Therapeutic Transcutaneous Ultrasound 
Following Thrombolysis: Results of the Perfusion by 
Thromobolytic and Ultrasound (PLUS) Trial
Michael P. Hudson, Adam B. Greenbaum, Laura Brenton, Miguel Fiol Sala, George R. 
McKendall, Jorge Bluguermann, E. Magnus Ohman, W. Douglas Weaver, Henry Ford 
Heart and Vascular Institute, Detroit, MI
Background: Therapeutic transcutaneous ultrasound (TUS) has been shown to
enhance thrombus dissolution and improve reperfusion success during thrombolysis
treatment.
Methods: In a double blind, randomized controlled, multicenter clinical trial, we random-
ized 396 patients to thrombolysis alone (control group) versus thrombolysis + TUS to
evaluate this adjunctive treatment in patients with acute ST-segment elevation myocardial
infarction (STEMI). We compared 60-minute TIMI grade flow, ST-segment resolution, and
other angiographic measures of perfusion plus clinical outcomes.
Results: Following interim analysis (n= 282), age (58 ± 10 vs. 55 ± 9 years), anterior inf-
arct location (33% vs. 33%), and symptom duration to thrombolysis (209 ± 164 vs. 198 ±
136 minutes) did not differ between control and TUS groups, respectively. Ultrasound
therapy was initiated 0.3 ± 3.6 minutes following thrombolysis with either rPA (37%) or
TNK-tPA (62%) and continued for 57 ± 8 minutes prior to protocol-mandated angiogra-
phy. Angiographic, ECG, and clinical outcomes are shown in Table.
Conclusions: Transcutaneous ultrasound, using pulsed energy, caused no mechanical
or device-related adverse events in STEMI patients receiving thrombolysis. Contrary to
our earlier animal and preclinical results using continuous wave energy, thrombolysis
plus pulsed wave TUS failed to improve TIMI flow grade, ST segment resolution, or myo-
cardial perfusion versus thrombolysis alone.
1061-96 Adrenomedullin Enhances Therapeutic Potency of Bone 
Marrow Transplantation for Acute Myocardial Infarction 
in Rats
Takafumi Fujii, Noritoshi Nagaya, Kazuhiro Nishigami, Hatsue Ishibashi-Ueda, Takashi 
Iwase, Takefumi Ito, Chikao Yutani, Shunji Sano, Hidezou Mori, National Cardiovascular 
Center Research Institute, Suita, Japan
Background: Adrenomedullin (AM) induces angiogenesis and inhibits endothelial cell
apoptosis through the PI3k/Akt pathway. Bone marrow transplantation has been shown
to induce angiogenesis in the ischemic heart. We investigated whether infusion of AM
enhances the therapeutic potency of bone marrow transplantation in rats with myocardial
infarction.
Methods: Immediately after coronary ligation, bone marrow-derived mononuclear cells
(MNCs) (5 ×106 cells) were injected into an ischemic area of myocardium in rats, followed
by subcutaneous infusion of 0.05µg/kg/min AM (AM-MNC group) or 0.9% saline (MNC-
group) for three days. Other rats received subcutaneous infusion of AM alone (AM group)
or saline (Control group) after coronary ligation.
Results: Hemodynamic and histological analyses were performed 4 weeks after treat-
ment. Left ventricular (LV) maximum dp/dt was significantly higher in the AM-MNC, MNC,
and AM groups than in the Control group (5076±201, 4083±262, and 4144±111 vs.
3338±97 mm Hg/s, P < 0.05). LV end-diastolic pressure was significantly lower in the
AM-MNC, MNC, and AM groups than in the Control group. Importantly, both parameters
were significantly improved in the AM-MNC group compared to those in the MNC and AM
groups. Infusion of AM significantly increased capillary density in ischemic myocardium,
suggesting angiogenic potency of AM. Interestingly, the capillary density was highest in
the AM-MNC group among the four groups. The number of TUNEL-positive cells in trans-
planted MNCs was smaller in the AM-MNC group than in the MNC group. In addition, the
number of lectin-positive cells (endothelial cells) in transplanted MNCs was larger in the
AM-MNC group than in the MNC group.
Conclusion: Infusion of AM enhanced the angiogenic potency of MNC transplantation,
resulting in marked improvement in cardiac function in rats with acute myocardial infarc-
tion. The beneficial effects of AM may be mediated by the anti-apoptotic effects and
angiogenic properties of AM itself.
1061-97 Efficacy of Granulocyte-Colony Stimulating Factor After 
Coronary Ligation in Rats: Evaluation by 
Echocardiographic Acoustic Quantification and 
Myocardial Contrast
Takashiro Hirano, Ryoko Azakami, Tomoko Kastuta, Kohei Okuda, Toshihiko Asanuma, 
Fuminobu Ishikura, Shintaro Beppu, Osaka University, Suita, Japan
Background and purpose:Granulocyte colony stimulating factor (G-CSF) reported to
improve the cardiac function after myocardial infarction (MI) by inducing bone marrow
cells (BMC), which differentiates into myocytes and vascular structures. The aim of this
study is to evaluate the effect of G-CSF after MI in the respect of myocardial perfusion,
remodeling and function.
Methods:The left coronary artery was ligated in 8 male rats after splenectomy. The
50µg/kg of G-CSF was injected under the skin once a day for 5 days before ligation and
given for 3 more days after ligation in 4 rats . Physiological saline was used as sham pro-
cedure in the other 4 rats. Ventricular area and its fractional area change (FAC) in the
short-axis were measured by the acoustic quantification method of SONOS 5500 (Phil-
ips) with high-frequency transducer. Non-perfused area was determined by intravenous
myocardial contrast echocardiography. Those data were measured before, just after, 2
and 4 weeks after coronary ligation.
Result:FAC decreased 2 weeks after ligation in both groups. During following 2 weeks,
however, it did not change in the G-CSF group (32.0±4.0 to 34.1±5.6% (ns)), while it
deteriorated significantly in the saline group (27.1±4.9 to 18.7±3.4%). Dilating ratio of
end diastolic area in the G-CSF group was smaller than that in the saline group at 4
weeks (4.2±0.9 vs. 6.6±0.3 p<0.01). The non-perfused area was significantly smaller in
the G-CSF group than the saline group 4 weeks after ligation (16.2±4.7 vs. 32.7±6.5%,
p<0.01), although it was almost identical between two groups just after ligation
(32.1±14.9 vs. 32.5±9.2%).
Conclusion:G-CSF should improve myocardial perfusion after coronary occlusion and
inhibit the left ventricular remodeling.
1061-98 Impaired Myocardial Perfusion Is a Major Explanation of 
the Poor Outcome Observed in Patients Undergoing 
Primary Angioplasty for ST-Segment Elevation 
Myocardial Infarction and Signs of Heart Failure
Giuseppe De Luca, Arnoud JW van't Hof, Harry Suryapranata, Jan Paul Ottervanger, AT 
Marcel Gosselink, Jan CA Hoorntje, Jan-Henk Dambrink, Felix Zijlstra, Menko-Jan de 
Boer, De Weezenlanden Hospital, Zwolle, The Netherlands
Background. The aim of the current study was to investigate the implication of myocar-
dial perfusion on outcome in patients with with ST-segment elevation myocardial infarc-
tion (STEMI) and signs of heart failure, treated with primary angioplasty.
Methods. Our population is represented by a cohort of 1548 consecutive patients with
STEMI underwent primary angioplasty. Congestive heart failure was defined as Killip
class > 1. All clinical, angiographic and follow-up data were prospectively collected. 
Results. Killip class was linearly associated with myocardial perfusion, and conse-
quently, with enzymatic infarct size, predischarge ejection fraction, and 1-year mortality
(see figure). Myocardial blush was independent predictor of 1-year mortality in patients
with advanced killip class at presentation.
Conclusions. Our study showed that patients with ventricular decompensation compli-
cating STEMI, have an impaired myocardial perfusion, that account for the poor outcome
observed in these patients. Thus, all the efforts should be aimed at improving myocardial
perfusion, beyond epicardial recanalization, in order to further improve the outcome of
these high-risk patients.
1061-99 Effects of L-Arginine in Myocardial Infarction: Double-
Blind, Placebo-Controlled Multicenter Pilot Study
Bronislaw Bednarz, Tomasz Chamiec, Leszek Ceremuzynski, and ARGAMI 
Investigators, Postgraduate Medical School, Warsaw, Poland
BACKGROUND. L-arginine, a substrate for nitric oxide has been shown to induce vasodi-
latation of the coronary vessels and thus is likely to improve perfusion of the ischemic
myocardium. The aim of the study was to assess the effect and safety of long-term treat-
ment with L-arginine on the clinical course of acute myocardial infarction with ST seg-
ment elevation ( STEMI ).
METHODS. 792 patients ( 551 men, mean age 64 years ) with STEMI up to 24h after the
onset of symptoms were randomized to oral L-arginine treatment ( 3.0 t.i.d for 30 days )
or placebo on the top of routine therapy. Main end points were: cardiovascular ( CV )
death, new non-fatal MI, stroke; secondary: in-hospital recurrent ischemia, serious
arrhythmias, heart failure calculated in all patients and in prespecified subgroups: diabe-
tes, hyperlipidemia, previous MI, hypertension.
RESULTS 
Thrombolysis
(n=141)
Thrombolysis +TUS
(n=141)
P value
TIMI Grade 3 Flow 50.4% 44.3% 0.34
> 50% ST-Segment Resolution 49.5% 48.8% 0.93
Corrected TIMI Frame Count < 40 46.7% 39.2% 0.27
TIMI Myocardial Perfusion “Blush” 
Grade 3
32.5% 38.3% 0.34
Death 3.8% 6.2% 0.32
Major Bleeding 3.8% 5.0% 0.61
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All values are: n (%). No differences were found in the other subgroups.
CONCLUSIONS. The results of this study, which is the first attempt to use L-arginine in
STEMI, showed that long-term oral L-arginine supplementation was well tolerated. Signif-
icant beneficial effects were found in patients with previous MI and also in those with
hyperlipidemia. In this relatively small study group a small positive trend was observed in
all patients, but larger trial is warranted to confirm or refute these promising preliminary
results.
1061-100 Predictors of Reinfarction After ST Elevation Myocardial 
Infarction and Glycoprotein Receptor Blockade: 
Analysis From the CADILLAC Trial
Gregory G. Pellizzon, Steve P. Marso, Cindy L. Grines, David A. Cox, Eulogio Garcia, 
James E. Tcheng, John J. Griffin, Giulio Guagliumi, Thomas Stuckey, Mark Turco, John 
D. Carroll, Alexandra J. Lansky, Roxana Mehran, Barry D. Rutherford, Gregg W. Stone, 
Mid America Heart Institute, Kansas City, MO, The Cardiovascular Research Foundation, 
New York, NY
Background: Risk factors for reinfarction after primary PCI utilizing contemporary tech-
niques, including stents and glycoprotein IIb/IIIa inhibitors, have not been described.
Methods: The clinical and angiographic correlates of reinfarction after primary PCI were
examined from the prospective, multicenter CADILLAC trial, in which 2,082 non shock
patients presenting with AMI within 12 hours of symptom onset were randomized to
PTCA vs. stenting, each + abciximab.
Results: Reinfarction occurred in 17 pts (0.8%) within 30 days, and in 48 pts (2.3%)
within 1 year after PCI. Reinfarction by 1 year occurred in 2.2% of pts after PTCA only,
2.9% after PTCA + abciximab, 2.2% after stenting alone, and 2.2% after stenting + abcix-
imab (P=0.85). Compared to pts without reinfarction, those with reinfarction more often
had hypertension (63% vs. 48%, P=0.06), insulin requiring diabetes (15% vs. 3.6%,
p=0.002), and LAD infarction (54% vs. 36%, p=0.01), but were less likely to be current
smokers (25% vs. 43%, p=0.01). The incidence of multivessel disease was similar in pts
with and without reinfarction. Procedural success (79% vs. 92%, p=0.007) and post-pro-
cedure minimal luminal diameter (2.26mm vs. 2.47mm, p=0.009) were lower in reinfarc-
tion pts, though final TIMI-3 flow rates were similar. By multivariate analysis, insulin
requiring diabetes (HR =7.25, 95% CI [2.5, 21.2], p=0.0003), LAD infarct vessel (HR =
2.7 [1.2, 6.0], p=0.02), and current smoking at baseline (HR = 0.45 [0.19, 1.08], p=0.07)
were independent predictors of reinfarction within 1 year. Specifically, reinfarction at 1-
year occurred in 8.8% of pts with insulin requiring diabetes vs 2.0% without this condition
(P=0.002), and in 3.4% of pts with LAD infarction vs 1.7% with non-LAD infarcts
(P=0.01).
Conclusion: Reinfarction rates after primary PCI of AMI are strikingly increased in
patients with insulin requiring diabetes, and are also greater in patients with anterior inf-
arction. Neither stents nor glycoprotein IIb/IIIa inhibitors reduce the rate of reinfarction
compared to balloon angioplasty. Close surveillance is warranted, and new strategies
deserve study to determine if the rate of reinfarction in these high risk subsets can be
reduced.
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801-1 In Women With Symptoms of Ischemic Heart Disease, 
Global and Regional Myocardial Perfusion Status by 
Magnetic Resonance Imaging Better Assigns Risk: 
Results From the National Heart, Lung, and Blood 
Institute-Sponsored Women's Ischemia Syndrome 
Evaluation (WISE)
Mark Doyle, Gerald M. Pohost, Eduardo Kortright, Leslee J. Shaw, Delia B. Johnson, 
William J. Rogers, Anthon Fuisz, Steven E. Reis, Barry L. Sharaf, Carl J. Pepine, Noel 
Bairey-Merz, Sunil Mankad, Diane A. Vido, Sheryl F. Kelsey, Marian B. Olson, Robert W 
W Biederman, Allegheny General Hospital, Pittsburgh, PA
Introduction The WISE study was organized to improve diagnostic tests for assigning
risk in women with symptoms of ischemic heart disease (IHD). MRI myocardial perfusion
imaging (MPI) can be quantitatively analyzed to calculate perfusion indices. The perfu-
sion indices can be used to assess the presence of regional ischemia or scar (RIS) or
averaged to generate a global myocardial perfusion index (GMPi).
Hypothesis We hypothesize that global assessment of myocardial perfusion better
assigns risk than assessment of regions of relative hypoperfusion.
Methods Women (n=133), mean age 56±11 (31-85) years, 32% minorities with symp-
toms of IHD underwent MR and single photon positron emission computed tomography
(SPECT) MPI evaluation. Follow-up was conducted over 38±14 months to monitor the
occurrence of myocardial infarction (MI) or all-cause death. Quantitative myocardial per-
fusion analysis was performed on MR data by registering first pass perfusion images,
extracting time intensity curves for the myocardium and normalizing using the left ventric-
ular blood pool signal. Integrating the normalized time intensity curve formed the GMPi.
Comparison of the normalized slopes and intensities between regions was used to detect
RIS. In a blinded manner, the MR and SPECT MPI data were used to categorize patients
as having a RIS; or by MR as having a GMPi in the lower 25th percentile.
Results At follow-up, 10 pts (7%) experienced an MI or death. Kaplan Meier event-free
survival analysis was performed and the log rank statistic calculated between low and
high risk groups for: SPECT RIS 1.99 (p=0.16), MR RIS, 1.03 (p=0.31); low MR GMPi,
6.78 (p < 0.01). Using the MR data, patients categorized as having either a low GMPi or
a RIS had a log rank statistic of 8.49 (p <0.005).
Conclusions
Kaplan Meier event-free survival analysis was used to assess time to cardiac death or MI
(n=10, 7%) and compared using a log rank statistic. A low MR GMPi was associated with
a 6.8-fold increased risk of death or MI (82% event-free survival as compared with 96%
event-free survival for those with a high MR GMPi. The presence of a low GMPi with RIS
data was a significantly better estimator of hard cardiac events than any sole hypoperfu-
sion index, SPECT or MRI.
9:30 a.m.
801-2 Predictors of Survival After Primary Percutaneous 
Coronary Intervention: The Impact of Myocardial 
Perfusion Grade in Female Patients
Ricardo A. Costa, Alexandra J. Lansky, Costantino O. Costantini, Yoshihiro Tsuchiya, 
Calin Caluser, Bahran Sahid, Martin Fahy, Eugenia Nikolsky, Eve Aymong, Manuela 
Negoita, Roxana Mehran, David A. Cox, Cindy L. Grines, Gregg W. Stone, 
Cardiovascular Research Foundation, New York, NY
Early epicardial (TIMI) and myocardial (MBG) reperfusion are predictors of survival in
patients with AMI. Whether MBG is equality predictive of survival for men and women is
unknown. Methods: 1,301 patients with AMI<12 hours without shock enrolled in the
CADILLAC trial underwent primary PCI. Post procedural MBG was analyzed at an inde-
pendent core lab, and classified as absent (MBG 0/1) or present (MBG 2/3). Results:
Compared to men (n=935), women (n=366) were older (57 vs. 67 yrs, p<0.001), had
more hypertension (43.4 vs. 59.8%, p,0.001), hyperlipidemia (36.5 vs. 45.4%, p=0.004),
diabetes (14.9 vs. 25.4%, p<0.001), less smoking (47.1 vs. 36.1%, p<0.001), and a
greater delay to mechanical reperfusion (3.8 vs.4.9 hrs, p<0.001). Women had lower
MBG 0/1 at baseline (91.2 vs. 86.7% women, p=0.02) and final procedure (50.8 vs.
43.2% women, p=0.02). One year survival curve for men and women are shown in the
tables below. By multivariate analysis, MBG 0/1 was a predictor of death at 1 year for all
women OR 5.15, 95%CI (1.98, 13.4), as well as for women with final TIMI 3 flow, OR
4.63, 95%CI (1.74, 12.3); but was not a predictor in men. Conclusions: Among women
undergoing primary PCI for AMI, the presence of impaired myocardial perfusion despite
normal epicardial perfusion is a strong independent predictor of mortality. 
Placebo Arginine P OR [95%CI]
All patients n=398 n=394
In-hospital CV death 32 (8.0) 28 (7.1) 0.23
CV death up to 6 months 41 (10.3) 35 (8.9) 0.39
In-hospital recurrent ischemia 33 (8.3) 24 (6.1) 0.66
Patients with previous MI n=54 n=51
In-hospital CV death 9 (16.7) 5 (9.8) 0.09
CVdeath up to 6 months 14 (25.9) 5 (9.8) 0.032 0.31[0.21,0.86]
Patients with hyperlipidemia n=113 n=114
In-hospital recurrent ischemia 14 (12.4) 3 (2.6) 0.005 0.19[0.06,0.64]
